Current Rheumatology Reports

, Volume 4, Issue 4, pp 351–358

Malignancy and systemic lupus erythematosus

  • Sasha Bernatsky
  • Ann Clarke
  • Rosalind Ramsey-Goldman

DOI: 10.1007/s11926-002-0045-6

Cite this article as:
Bernatsky, S., Clarke, A. & Ramsey-Goldman, R. Curr Rheumatol Rep (2002) 4: 351. doi:10.1007/s11926-002-0045-6


The association of malignancy with systemic lupus erythematosus (SLE) has been investigated for years. The findings of cohort studies lend support for an increased risk of malignancy in SLE but are difficult to interpret definitively. In addition, several cohort studies have suggested an increased risk of non-Hodgkin’s lymphoma but with imprecise estimation. There is inadequate evidence for any conclusions about the risk of solid tumors in these patients. A multicenter international research effort is in progress to elucidate these issues and to establish the role of exposures such as cytotoxic or immunomodulatory therapy. The recommendations advocated for cancer screening policies and for minimizing known risk factors for cancer in the general population should not be neglected in persons with SLE.

Copyright information

© Current Science Inc 2002

Authors and Affiliations

  • Sasha Bernatsky
  • Ann Clarke
  • Rosalind Ramsey-Goldman
    • 1
  1. 1.Division of Rheumatology, ArthritisNorthwestern UniversityChicagoUSA

Personalised recommendations